Reunion Neuroscience is committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for postpartum depression (PPD) ...
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results